Anavex Life Sciences Corp (AVXL)

[bas2020]

Not true...

we're going the AA route because a full approval is pretty much impossible without hitting it.

The last PR stated that one co-primary endpoint, with p < .025, and a secondary endpoint with same, is acceptable for the FDA to grant approval. You don't think Jin knows this?

Anavex is introducing the key biomarkers to cover the AA base, if the FDA would prefer that route.

The company is playing it very well.